Skip to content
Agree.net – Lifestyle
Author:
Rectify Pharmaceuticals, Inc.
Rectify Pharmaceuticals Presents Translational Data on RTY-406 at AASLD 2026 Liver Meeting
November 5, 2026
Rectify to Present Translational Data Supporting RTY-406 as a Transformative Therapy for PSC and Other Hepatobiliary Diseases
October 22, 2026
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
July 15, 2026
Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis
May 27, 2026
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026
May 13, 2026